The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer (Q83103181)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

2

Laurence Klotz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

3

Samir S Taneja

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Martin Gleave

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

81-86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Changes in body composition during androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Insulin sensitivity during combined androgen blockade for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Androgen deprivation therapy for prostate cancer: new concepts and concerns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

The development of androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Androgen-repressed phenotype in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Intermittent androgen suppression in prostate cancer: the Canadian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.025

10.1016/J.UROLONC.2008.07.025

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19111804%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference